Covid-19 cases in the UK have been picking up since November, with a 39% increase in positive tests in the last seven days alone.
Research shows that the UK is currently in a seasonal spike of Covid-19 infections, with November to April estimated to exhibit high disease activity.
Go deeper with GlobalData
Yet another vaccine was recently added to the UK’s fully approved line-up. In October 2023, Novavax’s prototype, Nuvaxovid, gained full marketing authorisation from the MHRA for use in individuals aged 12 and older. An updated vaccine was approved on 24 January. Nuvaxovid was originally greenlit under an emergency use authorisation in 2022.
Novavax CEO John Jacobs said in a 24 January statement announcing full approval of the updated vaccine: “Today’s MHRA authorisation is recognition of the role our vaccine can have in protecting the British public against Covid-19 this year.”
Nuvaxovid’s inclusion marked the entry of another protein subunit-based vaccine to those available in the UK. It joins long-standing vaccines present from near the beginning of the pandemic, including Pfizer/BioNTech’s Comirnaty and Moderna’s Spikevax, both mRNA vaccines, and Oxford/AstraZeneca’s viral vector-based Vaxzevria. Janssen and Valneva also have MHRA-approved vaccines.
GSK/Sanofi’s VidPrevtyn Beta, another protein-based Covid-19 vaccine, was approved for use as a booster in December 2022. HIPRA Human Health’s Bimervax was approved in August 2023, becoming the ninth Covid-19 vaccine authorised by the MHRA.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAmidst signs that Covid-19 will become a seasonally spiking virus, the UK’s autumn booster programme aims to reduce hospitalisations in those most at risk from severe disease. In the current programme, those aged 65 years and over are eligible, along with those who meet certain criteria.
Omicron BA.2.86 has emerged as the dominant variant throughout winter. While early indications show that it is no more dangerous than other variants, data is limited and the UK Health Security Agency (UKHSA) continues to monitor its circulation.
The UKHSA’s chief medical advisor, Professor Susan Hopkins, said in September 2023: “The autumn vaccination programme started this month, and this new [variant] data shows once again how important it is that the most vulnerable among us are fully vaccinated in order to receive the greatest possible protection.”
The UKHSA reported that last autumn’s booster programme resulted in patients being 53% less likely to be admitted to hospital with the disease in the 2–4 weeks following vaccination.
Away from prevention and looking at treatments, more than a million patients will soon gain access to Pfizer’s antiviral pill Paxlovid (nirmatrelvir/ritonavir). The drug is already recommended to an estimated 3.9 million people who meet certain criteria and, following recommendation by the National Institute of Care and Excellence, a further 1.4 million patients will be eligible.
Alongside Paxlovid, the NHS offers Veklury (remdesivir) from Gilead Sciences and MSD’s Lagevrio (molnupiravir). GSK/Vir Biotech’s Xevudy (sotrovimab) is a monoclonal antibody given to Covid-19 patients on the NHS who are unsuitable for antivirals.
Approved by the MHRA in December 2021, Paxlovid has been a source of high revenue for Pfizer. The antiviral saw peak global sales in 2022, totalling $18.9bn. Annual sales of the drug have since declined as the number of Covid-19 infections has fallen.
Paxlovid is currently transitioning to the US commercial market. The US commercial price for Paxlovid has been set at nearly $1,400 per five-day course – nearly triple what the US Government paid.
